Disc Medicine Aktie
WKN DE: A3D063 / ISIN: US2546041011
07.08.2025 18:24:14
|
Disc Medicine (IRON) Q2 Loss Widens 109%
Disc Medicine (NASDAQ:IRON), a clinical-stage biopharmaceutical company advancing treatments for hematologic diseases, released its second quarter 2025 earnings on August 7, 2025. Reflecting investments in critical clinical programs, the period showed progress on pipeline milestones but highlighted accelerating losses associated with ramping up for late-stage trials and potential commercialization. Source: Analyst estimates for the quarter provided by FactSet. Disc Medicine is focused on discovering and developing therapies for patients suffering from serious blood disorders. The company does not yet sell any commercial products; instead, it invests heavily in the clinical testing of new molecules.Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Disc Medicine Inc Registered Shsmehr Nachrichten
Keine Nachrichten verfügbar. |
Analysen zu Disc Medicine Inc Registered Shsmehr Analysen
Aktien in diesem Artikel
Disc Medicine Inc Registered Shs | 62,39 | 0,37% |
|
Q2 Holdings Inc | 62,00 | -0,80% |
|